Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16615835 | 0.85 | KMT2A (0.53) | SMN1; SMN2ALDH1A1KDM4EHSD17B10LMNA | |
| SCHEMBL16598218 | 0.83 | GRIN2A (0.55) | SMN1; SMN2ALDH1A1NPSR1LMNAGRIN1 | |
| SCHEMBL16615881 | 0.80 | GRIN2A (0.50) | ALDH1A1LMNAGRIN1GRIN2APKM | |
| SCHEMBL16615803 | 0.79 | GRIN2A (0.52) | ALDH1A1LMNAGRIN1GRIN2AKMT2A | |
| SCHEMBL16615838 | 0.79 | GRIN2A (0.47) | SMN1; SMN2ALDH1A1GRIN1GRIN2AKMT2A | |
| SCHEMBL16615799 | 0.79 | GRIN2A (0.50) | ALDH1A1GRIN1GRIN2APKMKMT2A | |
| SCHEMBL16598435 | 0.79 | GRIN2A (0.61) | SMN1; SMN2ALDH1A1LMNAGRIN1GRIN2A | |
| SCHEMBL16615836 | 0.78 | GRIN2A (0.49) | ALDH1A1NPSR1GRIN1GRIN2APKM | |
| SCHEMBL16598124 | 0.78 | GRIN2A (0.60) | SMN1; SMN2ALDH1A1LMNAGRIN1GRIN2A | |
| SCHEMBL16598092 | 0.77 | GRIN2A (0.61) | ALDH1A1GRIN1GRIN2AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963434-B2 | N-arylmethyl sulfonamide negative modulators of NR2A | LUC THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963434-B2 | N-arylmethyl sulfonamide negative modulators of NR2A | LUC THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2015048503-A2 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | MNEMOSYNE PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311782-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | GRIN2A, GRIN2B, NR2C2 | SMN1; SMN2 360/4885ALDH1A1 3274/4885KDM4E 2241/4885 |
| US-20150141433-A1 | N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A | GRIN2A, GRIN2B, NR2C2 | SMN1; SMN2 360/4885ALDH1A1 3274/4885KDM4E 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.